4.7 Article

Presence and clinical impact of human herpesvirus-6 infection in patients with moderate to critical coronavirus disease-19

Journal

JOURNAL OF MEDICAL VIROLOGY
Volume 94, Issue 3, Pages 1212-1216

Publisher

WILEY
DOI: 10.1002/jmv.27392

Keywords

COVID-19; herpesvirus-6; HHV-6

Categories

Funding

  1. Ministerio da Ciencia, Tecnologia e Inovacao
  2. Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
  3. Conselho Nacional de Desenvolvimento Cientifico e Tecnologico

Ask authors/readers for more resources

This real-world pilot study aimed to understand the frequency and clinical impact of HHV-6 coinfection in moderate to critically ill patients hospitalized due to COVID-19. Despite the high frequency of HHV-6 coinfection in SARS-CoV-2 positive cases, it did not impact general mortality. More extensive prospective studies are suggested to further elucidate the influence of HHV-6 reactivation in COVID-19 cases, focusing on specific clinical outcomes and viral reactivation mechanisms.
Human herpesvirus-6 (HHV-6) may cause serious diseases in immunocompromised individuals. SARS-CoV-2/HHV-6 coinfection has been emphasized in previous works, mostly case reports, small series, or epidemiological studies, but few are known about its real clinical outcomes. Here we present a real-world pilot study aiming to understand the frequency and the clinical impact of HHV-6 coinfection in moderate to critically ill patients hospitalized due to COVID-19. SARS-CoV-2 and HHV-6 were evaluated in nasopharyngeal samples at the hospital admission of suspected COVID-19 patients. From 173 consecutive cases, 60 were SARS-CoV-2 positive and 13/60 (21.7%) were HHV-6 positive after identified as the HHV-6B species by a Sanger sequencing. The SARS-CoV-2+/HHV-6+ group was younger but not significant for cardiovascular diseases, diabetes, obesity, and cancer, but significant among therapeutic immunosuppressed patients (as systemic lupus erythematosus and kidney transplant patients). In the medical records, only sparse data on cutaneous or neurological manifestations were found. Biochemical and hematological data showed only a trend towards hyperferritinemic status and lymphopenia. In conclusion, despite the impressive high frequency of HHV-6 coinfection in SARS-CoV-2 positive cases, it did not impact general mortality. We suggest larger future prospective studies to better elucidate the influence of HHV-6 reactivation in cases of COVID-19, designed to specific assessment of clinical outcomes and viral reactivation mechanisms.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available